Bristol-Myers Squibb confirms Bancroft as permanent CFO; PhRMA co-opts AstraZeneca's Davis pending Tauzin replacement
US drug major Bristol-Myers Squibb yesterday elected Charles Bancroft as chief financial officer effective April 8. In this role, which he has held in an interim capacity since January 1, filing the position left by the resignation of Marc Huet, Mr Bancroft will be responsible for directing and managing the company's fiscal operations and the global finance organization. He will report to Lamberto Andreotti, president, chief operating officer and chief executive officer designate, and due to take over as CEO when Jim Cornelius retires on May 4.
Mr Bancroft joined B-MS in 1984 and has since held positions of increasing responsibility within the finance organization, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec.
AstraZeneca's Chip Davis joins PhRMA to assist organization in leadership transition
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze